Citigroup’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-17,118
| Closed | -$813K | – | 6031 |
|
|
2025
Q3 | $813K | Sell |
17,118
-29,418
| -63% | -$1.42M | ﹤0.01% | 3295 |
|
|
2025
Q2 | $2.48M | Sell |
46,536
-187,636
| -80% | -$8.53M | ﹤0.01% | 2448 |
|
|
2025
Q1 | $9.48M | Buy |
234,172
+146,255
| +166% | +$6.2M | ﹤0.01% | 1400 |
|
|
2024
Q4 | $2.45M | Buy |
87,917
+36,036
| +69% | +$1.09M | ﹤0.01% | 2643 |
|
|
2024
Q3 | $1.49M | Buy |
51,881
+22,612
| +77% | +$590K | ﹤0.01% | 2927 |
|
|
2024
Q2 | $687K | Sell |
29,269
-226,165
| -89% | -$4.84M | ﹤0.01% | 3178 |
|
|
2024
Q1 | $6.45M | Buy |
255,434
+66,982
| +36% | +$1.61M | ﹤0.01% | 1538 |
|
|
2023
Q4 | $4.4M | Buy |
188,452
+91,962
| +95% | +$1.81M | ﹤0.01% | 1676 |
|
|
2023
Q3 | $4.88M | Buy |
96,490
+23,955
| +33% | +$1.12M | ﹤0.01% | 1445 |
|
|
2023
Q2 | $3.39M | Sell |
72,535
-60,982
| -46% | -$2.79M | ﹤0.01% | 1767 |
|
|
2023
Q1 | $5.11M | Buy |
133,517
+50,458
| +61% | +$2.25M | ﹤0.01% | 1497 |
|
|
2022
Q4 | $4.55M | Buy |
83,059
+80,860
| +3,677% | +$3.46M | ﹤0.01% | 1520 |
|
|
2022
Q3 | $75K | Sell |
2,199
-1,878
| -46% | -$28.7K | ﹤0.01% | 4219 |
|
|
2022
Q2 | $39K | Sell |
4,077
-8,742
| -68% | -$91.1K | ﹤0.01% | 4646 |
|
|
2022
Q1 | $182K | Sell |
12,819
-37,025
| -74% | -$648K | ﹤0.01% | 4124 |
|
|
2021
Q4 | $1.05M | Buy |
49,844
+18,563
| +59% | +$412K | ﹤0.01% | 3199 |
|
|
2021
Q3 | $699K | Sell |
31,281
-44,563
| -59% | -$1.01M | ﹤0.01% | 3372 |
|
|
2021
Q2 | $1.88M | Buy |
75,844
+15,717
| +26% | +$442K | ﹤0.01% | 2708 |
|
|
2021
Q1 | $1.74M | Buy |
60,127
+55,762
| +1,277% | +$1.69M | ﹤0.01% | 2589 |
|
|
2020
Q4 | $113K | Buy |
4,365
+1,079
| +33% | +$30K | ﹤0.01% | 5439 |
|
|
2020
Q3 | $101K | Sell |
3,286
-4,449
| -58% | -$155K | ﹤0.01% | 5095 |
|
|
2020
Q2 | $193K | Buy |
7,735
+3,052
| +65% | +$69.7K | ﹤0.01% | 5036 |
|
|
2020
Q1 | $99K | Buy |
4,683
+1,496
| +47% | +$32.1K | ﹤0.01% | 5344 |
|
|
2019
Q4 | $71K | Buy |
3,187
+2,976
| +1,410% | +$61.6K | ﹤0.01% | 6036 |
|
|
2019
Q3 | $5K | Buy |
+211
| New | +$4.91K | ﹤0.01% | 7311 |
|
Other funds holding AKRO
Citigroup's AKRO Position: Q4 2025 in Review
Citigroup sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 17,118 shares — an estimated $813K sold.
Citigroup first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $9.48M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Citigroup reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Citigroup sold 17,118 Akero Therapeutics shares in Q4 2025, an estimated $813K.
- Citigroup first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Citigroup's Akero Therapeutics position peaked at $9.48M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.